Literature DB >> 33427414

Role of glomerular filtration rate-modifying drugs in the development of anticoagulant-related nephropathy.

Ajay K Medipally1, Min Xiao1, Brad H Rovin2, Anjali A Satoskar1, Iouri Ivanov1, Shahzeb Qaisar1, Sergey V Brodsky1.   

Abstract

INTRODUCTION: Anticoagulant-related nephropathy (ARN), that was described in humans first as warfarin-related nephropathy, is characterized by acute kidney injury and red blood cell (RBC) tubular casts in the kidney. 5/6 nephrectomy (5/7NE) rats treated with warfarin or dabigatran show changes in kidney function and morphology that are similar to human disease. The role of glomerular filtration rate (GFR) in the pathogenesis of ARN is not clear. The aim of these studies was to elucidate the role of GFR in the pathogenesis of dabigatran-induced ARN in 5/6NE rats.
METHODS: 5/6NE rats were treated per os with 150 mg/kg/day dabigatran alone or with drugs that lower (enalapril, 1.5 mg/kg/day) or increase (albuterol, 4.0 mg/kg/day) GFR for 7 days. Changes in coagulation and kidney function were recorded daily. Kidney morphology was evaluated on day 7 after the treatment.
RESULTS: Dabigatran resulted in activated partial thromboplastin time increase that was not affected by GFR-modifying drugs. Blood pressure was significantly lower in 5/6NE rats treated with enalapril and dabigatran as compared to dabigatran alone. The GFR was decreased by 35% in enalapril/dabigatran- and increased by 26% in albuterol/dabigatran-treated animals. There were no changes in serum creatinine, hematuria or urinary kidney injury molecule (KIM-1) levels when GFR-modifying drugs were added to dabigatran. All dabigatran-treated animals had RBC casts in the kidney regardless of the GFR modification.
CONCLUSIONS: GFR does not play a significant role in the dabigatran-induced acute kidney injury in 5/6 nephrectomy model in rats. Based in these data, modification of GFR in patients with ARN is not warranted.
© 2021 The Authors. Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society.

Entities:  

Keywords:  5/6 nephrectomy; anticoagulant-related nephropathy; glomerular filtration rate

Mesh:

Substances:

Year:  2021        PMID: 33427414      PMCID: PMC7798050          DOI: 10.14814/phy2.14697

Source DB:  PubMed          Journal:  Physiol Rep        ISSN: 2051-817X


  30 in total

1.  Warfarin-related nephropathy modeled by nephron reduction and excessive anticoagulation.

Authors:  Kyle Ware; Polina Brodsky; Anjali A Satoskar; Tibor Nadasdy; Gyongyi Nadasdy; Haifeng Wu; Brad H Rovin; Udayan Bhatt; Jon Von Visger; Lee A Hebert; Sergey V Brodsky
Journal:  J Am Soc Nephrol       Date:  2011-09-01       Impact factor: 10.121

2.  Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats.

Authors:  Margaret Ryan; Kyle Ware; Zahida Qamri; Anjali Satoskar; Haifeng Wu; Gyongyi Nadasdy; Brad Rovin; Lee Hebert; Tibor Nadasdy; Sergey V Brodsky
Journal:  Nephrol Dial Transplant       Date:  2013-09-05       Impact factor: 5.992

3.  Reversing glomerular hypertension stabilizes established glomerular injury.

Authors:  T W Meyer; S Anderson; H G Rennke; B M Brenner
Journal:  Kidney Int       Date:  1987-03       Impact factor: 10.612

4.  Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate.

Authors:  Sergey V Brodsky; Tibor Nadasdy; Brad H Rovin; Anjali A Satoskar; Gyongyi M Nadasdy; Haifeng M Wu; Udayan Y Bhatt; Lee A Hebert
Journal:  Kidney Int       Date:  2011-03-09       Impact factor: 10.612

5.  Pharmacological characterization and anatomical localization of prejunctional beta-adrenoceptors in the rat kidney.

Authors:  P P Lakhlani; F Amenta; P Napoleone; L Felici; D C Eikenburg
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

6.  Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation.

Authors:  T H Hostetter; J L Olson; H G Rennke; M A Venkatachalam; B M Brenner
Journal:  Am J Physiol       Date:  1981-07

Review 7.  Nondiabetic consequences of obesity on kidney.

Authors:  Tarak Srivastava
Journal:  Pediatr Nephrol       Date:  2006-02-21       Impact factor: 3.714

Review 8.  Permeability factors in focal and segmental glomerulosclerosis.

Authors:  Jochen Reiser; Cynthia C Nast; Nada Alachkar
Journal:  Adv Chronic Kidney Dis       Date:  2014-09       Impact factor: 3.620

9.  Glomerular volume and renal function in children with different types of the nephrotic syndrome.

Authors:  E Nyberg; S O Bohman; U Berg
Journal:  Pediatr Nephrol       Date:  1994-06       Impact factor: 3.714

View more
  4 in total

1.  IgA Nephropathy Is the Most Common Underlying Disease in Patients With Anticoagulant-Related Nephropathy.

Authors:  Hernando Trujillo; Justo Sandino; Teresa Cavero; Fernando Caravaca-Fontán; Eduardo Gutiérrez; Ángel M Sevillano; Amir Shabaka; Gema Fernández-Juárez; Pablo Rodríguez Doyágüez; Rocío Gimena Muñoz; Leonardo Calle García; Virginia Cabello; José Manuel Muñoz-Terol; Ana García Santiago; Oscar Toldos; Juan Antonio Moreno; Manuel Praga
Journal:  Kidney Int Rep       Date:  2022-01-19

2.  Role of glomerular filtration rate-modifying drugs in the development of anticoagulant-related nephropathy.

Authors:  Ajay K Medipally; Min Xiao; Brad H Rovin; Anjali A Satoskar; Iouri Ivanov; Shahzeb Qaisar; Sergey V Brodsky
Journal:  Physiol Rep       Date:  2021-01

3.  Chronic Hematuria Increases Chronic Kidney Injury and Epithelial-Mesenchymal Transition in 5/6 Nephrectomy Rats.

Authors:  Min Xiao; Ajay K Medipally; Laura Biederman; Anjali A Satoskar; Iouri Ivanov; Brad H Rovin; Sergey V Brodsky
Journal:  Front Med (Lausanne)       Date:  2021-11-25

4.  Role of protease-activated receptor-1 (PAR-1) in the glomerular filtration barrier integrity.

Authors:  Ajay Medipally; Min Xiao; Laura Biederman; Anjali A Satoskar; Iouri Ivanov; Brad Rovin; Samir Parikh; Bryce A Kerlin; Sergey V Brodsky
Journal:  Physiol Rep       Date:  2022-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.